KR102417522B1 - Composition for osteogenesis containing calcium, collagen and PGA - Google Patents
Composition for osteogenesis containing calcium, collagen and PGA Download PDFInfo
- Publication number
- KR102417522B1 KR102417522B1 KR1020210164614A KR20210164614A KR102417522B1 KR 102417522 B1 KR102417522 B1 KR 102417522B1 KR 1020210164614 A KR1020210164614 A KR 1020210164614A KR 20210164614 A KR20210164614 A KR 20210164614A KR 102417522 B1 KR102417522 B1 KR 102417522B1
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- calcium
- parts
- vitamin
- phosphate
- Prior art date
Links
- 239000011575 calcium Substances 0.000 title claims abstract description 47
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title claims abstract description 46
- 229910052791 calcium Inorganic materials 0.000 title claims abstract description 46
- 239000000203 mixture Substances 0.000 title claims abstract description 40
- 102000008186 Collagen Human genes 0.000 title claims description 31
- 108010035532 Collagen Proteins 0.000 title claims description 31
- 229920001436 collagen Polymers 0.000 title claims description 31
- 230000011164 ossification Effects 0.000 title description 3
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims abstract description 46
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims abstract description 36
- 239000001506 calcium phosphate Substances 0.000 claims abstract description 35
- 229910000389 calcium phosphate Inorganic materials 0.000 claims abstract description 32
- 235000011010 calcium phosphates Nutrition 0.000 claims abstract description 32
- 235000015097 nutrients Nutrition 0.000 claims abstract description 27
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical class C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims abstract description 25
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Chemical class C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 24
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000011647 vitamin D3 Chemical class 0.000 claims abstract description 24
- 235000005282 vitamin D3 Nutrition 0.000 claims abstract description 24
- 229940021056 vitamin d3 Drugs 0.000 claims abstract description 24
- 150000003751 zinc Chemical class 0.000 claims abstract description 24
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical class [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 claims abstract description 23
- 229940011671 vitamin b6 Drugs 0.000 claims abstract description 23
- 239000011726 vitamin B6 Substances 0.000 claims abstract description 22
- 235000019158 vitamin B6 Nutrition 0.000 claims abstract description 22
- 125000003748 selenium group Chemical class *[Se]* 0.000 claims abstract 4
- 241000251468 Actinopterygii Species 0.000 claims description 27
- 239000004137 magnesium phosphate Substances 0.000 claims description 18
- 229910000157 magnesium phosphate Inorganic materials 0.000 claims description 18
- 229960002261 magnesium phosphate Drugs 0.000 claims description 18
- 235000010994 magnesium phosphates Nutrition 0.000 claims description 18
- 229960001714 calcium phosphate Drugs 0.000 claims description 11
- 239000004220 glutamic acid Substances 0.000 claims description 11
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 5
- 235000013922 glutamic acid Nutrition 0.000 claims description 5
- 230000037182 bone density Effects 0.000 abstract description 4
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000011701 zinc Chemical class 0.000 abstract 1
- 229910052725 zinc Inorganic materials 0.000 abstract 1
- 150000003342 selenium Chemical class 0.000 description 19
- 230000000694 effects Effects 0.000 description 12
- 230000004072 osteoblast differentiation Effects 0.000 description 7
- 206010010774 Constipation Diseases 0.000 description 6
- 201000006549 dyspepsia Diseases 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 208000024798 heartburn Diseases 0.000 description 6
- 229940069978 calcium supplement Drugs 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 235000015110 jellies Nutrition 0.000 description 5
- 239000008274 jelly Substances 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000002253 acid Substances 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229910000400 magnesium phosphate tribasic Inorganic materials 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 3
- 235000019731 tricalcium phosphate Nutrition 0.000 description 3
- 229940078499 tricalcium phosphate Drugs 0.000 description 3
- 229940033158 vitamin b6 1 mg Drugs 0.000 description 3
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 208000010643 digestive system disease Diseases 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000004211 gastric acid Anatomy 0.000 description 2
- 208000018685 gastrointestinal system disease Diseases 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010006956 Calcium deficiency Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010049088 Osteopenia Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- HFVAFDPGUJEFBQ-UHFFFAOYSA-M alizarin red S Chemical compound [Na+].O=C1C2=CC=CC=C2C(=O)C2=C1C=C(S([O-])(=O)=O)C(O)=C2O HFVAFDPGUJEFBQ-UHFFFAOYSA-M 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 229910000394 calcium triphosphate Inorganic materials 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000000752 ionisation method Methods 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- RFWLACFDYFIVMC-UHFFFAOYSA-D pentacalcium;[oxido(phosphonatooxy)phosphoryl] phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O RFWLACFDYFIVMC-UHFFFAOYSA-D 0.000 description 1
- KFHHGNBIPJDZPH-UHFFFAOYSA-D pentamagnesium [oxido(phosphonatooxy)phosphoryl] phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O KFHHGNBIPJDZPH-UHFFFAOYSA-D 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229960003581 pyridoxal Drugs 0.000 description 1
- 235000008164 pyridoxal Nutrition 0.000 description 1
- 239000011674 pyridoxal Substances 0.000 description 1
- 235000008151 pyridoxamine Nutrition 0.000 description 1
- 239000011699 pyridoxamine Substances 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/275—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of animal origin, e.g. chitin
- A23L29/281—Proteins, e.g. gelatin or collagen
- A23L29/284—Gelatin; Collagen
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/306—Foods, ingredients or supplements having a functional effect on health having an effect on bone mass, e.g. osteoporosis prevention
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/15—Inorganic Compounds
- A23V2250/156—Mineral combination
- A23V2250/1626—Selenium
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
- A23V2250/704—Vitamin B
- A23V2250/7046—Vitamin B3 niacin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
- A23V2250/704—Vitamin B
- A23V2250/7052—Vitamin B6
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
본 발명은 골생성을 돕는 칼슘 콜라겐 PGA 함유 조성물에 관한 것으로, 구체적으로 기존 칼슘 영양제의 단점인 속쓰림, 변비 등의 단점을 개선하면서도 체내에 칼슘 성분이 효율적으로 흡수될 수 있도록 하며 골밀도를 효과적으로 높일 수 있는 칼슘 영양제 조성물에 관한 것이다.The present invention relates to a composition containing calcium collagen PGA that helps bone formation, and specifically, it can improve the disadvantages of heartburn, constipation, etc. It relates to a calcium nutrient composition.
칼슘은 우리 몸에서 뼈와 치아의 형성 및 유지에 필요한 무기질로, 우리 몸에 존재하는 대부분 칼슘은 뼈에 존재한다. 또한 칼슘은 근육 및 세포외액 등의 여러 조직에도 존재하며 각 조직에서 중요한 역할을 담당한다. 따라서 이러한 칼슘이 부족하게 되면 관련된 질환이 생길 수 있다.Calcium is a mineral necessary for the formation and maintenance of bones and teeth in our body. Most of the calcium in our body is present in bones. Calcium is also present in various tissues, such as muscle and extracellular fluid, and plays an important role in each tissue. Therefore, this calcium deficiency can cause related diseases.
체내 칼슘 부족으로 인해 발생하는 대표적인 질환으로 골다공증 및 골감소증을 들 수 있으며, 이들 질환이 발생하게 되면 작은 충격에도 뼈가 부러질 수 있다. 또한 체내 칼슘 부족은 성장기 뼈 형성에 악영향을 미칠 수 있고 근육 또는 신경 이상을 유발할 수도 있다.Osteoporosis and osteopenia are representative diseases caused by lack of calcium in the body, and when these diseases occur, even a small impact can break bones. In addition, lack of calcium in the body may adversely affect bone formation during growth and may cause muscle or nerve abnormalities.
이러한 체내 칼슘 부족을 해결하기 위해 칼슘이 다량 함유된 식품을 섭취하는 것이 좋지만, 바쁜 현대인들에게는 이러한 식생활을 유지하는 것이 어렵기 때문에 이를 위해 체내 칼슘을 보충하기 위한 다양한 칼슘 영양제(또는 칼슘 보충제)가 개발되어 시중에서 판매되고 있다.In order to solve this lack of calcium in the body, it is recommended to eat foods rich in calcium, but it is difficult for busy modern people to maintain such a diet. developed and marketed.
하지만 기존의 칼슘 영양제들은 복용 시 속쓰림, 변비, 구역질 등의 부작용을 유발할 수 있다는 단점이 있어 이를 개선할 필요가 있으며, 체내 칼슘의 흡수 효율을 높이고 궁극적으로는 뼈의 형성에 보다 우수한 효과를 발휘할 수 있도록 개선된 칼슘 영양제가 필요하다.However, existing calcium supplements have the disadvantage that they can cause side effects such as heartburn, constipation, and nausea when taken, so they need to be improved. There is a need for improved calcium nutritional supplements.
따라서 본 발명의 주된 목적은 기존 칼슘 영양제의 단점인 속쓰림, 변비 등의 부작용 문제를 개선하면서도 체내에 칼슘 성분이 효율적으로 흡수될 수 있도록 하며 골밀도를 효과적으로 높일 수 있는 칼슘 영양제 조성물을 제공하는데 있다.Therefore, the main object of the present invention is to provide a calcium nutrient composition that can efficiently absorb calcium components into the body and effectively increase bone density while improving side effects such as heartburn and constipation, which are disadvantages of existing calcium supplements.
본 발명의 한 양태에 따르면, 본 발명은 인산칼슘, 비타민 D3, 인산마그네슘, 아연염, 셀레늄염 및 비타민 B6을 포함하며, 인산칼슘 100중량부를 기준으로 비타민 D3 0.0002 내지 0.005중량부, 인산마그네슘 30 내지 50중량부, 아연염 0.2 내지 5중량부, 셀레늄염 0.00004 내지 0.001중량부 및 비타민 B6 0.04 내지 1중량부로 포함하는 칼슘 영양제 조성물을 제공한다.According to one embodiment of the present invention, the present invention includes calcium phosphate, vitamin D3, magnesium phosphate, zinc salt, selenium salt and vitamin B6, based on 100 parts by weight of calcium phosphate, vitamin D3 0.0002 to 0.005 parts by weight, magnesium phosphate 30 to 50 parts by weight, zinc salt 0.2 to 5 parts by weight, selenium salt 0.00004 to 0.001 parts by weight, and vitamin B6 0.04 to 1 part by weight provides a calcium nutrient composition comprising.
본 발명의 칼슘 영양제 조성물에 있어서, 인산칼슘 100중량부를 기준으로 피쉬콜라겐 150 내지 250중량부를 더 포함하는 것이 바람직하다.In the calcium nutrient composition of the present invention, it is preferable to further include 150 to 250 parts by weight of fish collagen based on 100 parts by weight of calcium phosphate.
본 발명의 칼슘 영양제 조성물에 있어서, 인산칼슘 100중량부를 기준으로 폴리감마글루탐산 4 내지 10중량부를 더 포함하는 것이 바람직하다.In the calcium nutrient composition of the present invention, it is preferable to further include 4 to 10 parts by weight of polygamma-glutamic acid based on 100 parts by weight of calcium phosphate.
본 발명의 칼슘 영양제 조성물에 있어서, 1일 용량당 800 내지 1200㎎으로 인산칼슘을 포함하는 것이 바람직하다.In the calcium nutrient composition of the present invention, it is preferable to include calcium phosphate in an amount of 800 to 1200 mg per daily dose.
본 발명의 칼슘 영양제 조성물은 기존 칼슘 영양제의 단점인 속쓰림(위장 장애), 변비 등의 단점을 개선하면서도 체내에 칼슘 성분이 효율적으로 흡수될 수 있도록 하며 골밀도를 효과적으로 높일 수 있다.The calcium nutrient composition of the present invention can improve the disadvantages of existing calcium nutrient agents, such as heartburn (gastrointestinal disorder) and constipation, while allowing the calcium component to be efficiently absorbed into the body and can effectively increase bone density.
도 1 내지 3은 본 발명의 칼슘 영양제 조성물이 조골세포 분화에 미치는 영향을 실험한 결과이다. '칼슘복합물': 인산칼슘, 비타민 D3, 인산마그네슘, 가용성 아연염(2가), 가용성 셀레늄염(6가) 및 비타민 B6의 혼합물을 처리한 제1실험군; '칼슘복합물+콜라겐5%': 제1실험군에 추가로 피쉬콜라겐을 처리한 제2실험군; '칼슘복합물+콜라겐5%+PGA': 제2실험군에 추가로 폴리감마글루탐산을 처리한 제3실험군.1 to 3 are results of testing the effect of the calcium nutrient composition of the present invention on osteoblast differentiation. 'Calcium complex': the first experimental group treated with a mixture of calcium phosphate, vitamin D3, magnesium phosphate, soluble zinc salt (divalent), soluble selenium salt (hexavalent) and vitamin B6; 'Calcium complex + collagen 5%': the second experimental group treated with fish collagen in addition to the first experimental group; 'Calcium complex + Collagen 5% + PGA': Experimental group 3 treated with polygamma-glutamic acid in addition to the second experimental group.
본 발명의 칼슘 영양제 조성물은 인산칼슘, 비타민 D3, 인산마그네슘, 아연염, 셀레늄염 및 비타민 B6을 포함하며, 인산칼슘 100중량부를 기준으로 비타민 D3 0.0002 내지 0.005중량부, 인산마그네슘 30 내지 50중량부, 아연염 0.2 내지 5중량부, 셀레늄염 0.00004 내지 0.001중량부 및 비타민 B6 0.04 내지 1중량부로 포함하는 것을 특징으로 한다.The calcium nutrient composition of the present invention includes calcium phosphate, vitamin D3, magnesium phosphate, zinc salt, selenium salt and vitamin B6, based on 100 parts by weight of calcium phosphate, vitamin D3 0.0002 to 0.005 parts by weight, magnesium phosphate 30 to 50 parts by weight , 0.2 to 5 parts by weight of zinc salt, 0.00004 to 0.001 parts by weight of selenium salt, and 0.04 to 1 part by weight of vitamin B6.
상기 본 발명 칼슘 영양제 조성물의 각 성분 및 이들의 비율로 인해 기존 칼슘 영양제의 단점인 복용 시 속쓰림(위장 장애), 변비 등을 유발하는 문제의 개선과 동시에 복용 대상의 체내 칼슘 성분의 효율적인 흡수 및 골밀도 개선이 가능하다.Due to each component and their ratio of the calcium nutrient composition of the present invention, the problem of heartburn (gastrointestinal disorder), constipation, etc., which are disadvantages of the existing calcium nutrient, is improved, and at the same time, the effective absorption and bone density of the calcium component in the body of the subject is improved. improvement is possible
기존의 칼슘 영양제에 주성분으로 활용되는 것은 구연산칼슘 또는 탄산칼슘인데 이들은 위에서 위산에 의해 이온화되어 위벽으로 일부 흡수되지만 위벽을 손상 또는 자극하여 속쓰림을 유발하고 변비를 유발하는 부작용이 있다.Calcium citrate or calcium carbonate used as the main ingredient in existing calcium supplements is ionized by gastric acid in the stomach and partially absorbed into the stomach wall, but has side effects of damaging or stimulating the stomach wall, causing heartburn and constipation.
반면 본 발명의 칼슘 영양제 조성물은 특히 인산칼슘을 사용함으로써, 위산에 의해서 빨리 이온화되지 않고 서서히 이온화 과정을 거치면서 위벽에 영향을 거의 미치치 않으며, 소장에서 서서히 흡수될 수 있다. 또한 칼슘이 갑자기 많은 양이 소장으로 들어오더라도 흡수되는 양에 한계가 있어, 인산칼슘을 사용하는 본 발명의 칼슘 영양제 조성물이 탄산칼슘과 같이 빨리 이온화되는 칼슘을 사용하는 기존의 제제들 보다 안전하고 효과적일 수 있다.On the other hand, the calcium nutrient composition of the present invention, particularly by using calcium phosphate, is not rapidly ionized by gastric acid and has little effect on the gastric wall while slowly undergoing an ionization process, and can be slowly absorbed in the small intestine. In addition, even if a large amount of calcium suddenly enters the small intestine, there is a limit to the amount absorbed, so the calcium nutrient composition of the present invention using calcium phosphate is safer and safer than existing formulations using calcium that is ionized quickly, such as calcium carbonate. It can be effective.
상기와 같은 효과를 위해, 인산칼슘, 비타민 D3, 인산마그네슘, 아연염, 셀레늄염 및 비타민 B6의 비율을, 보다 바람직하게는, 인산칼슘 100중량부를 기준으로, 비타민 D3 0.0005 내지 0.002중량부, 인산마그네슘 35 내지 45중량부, 아연염 0.5 내지 2중량부, 셀레늄염 0.0001 내지 0.0004중량부 및 비타민 B6 0.1 내지 0.4중량부로 하고, 더욱 바람직하게는 인산칼슘 100중량부를 기준으로, 비타민 D3 0.0007 내지 0.0015중량부, 인산마그네슘 37 내지 43중량부, 아연염 0.7 내지 1.5중량부, 셀레늄염 0.00015 내지 0.0003중량부 및 비타민 B6 0.15 내지 0.3중량부로 한다.For the above effects, the ratio of calcium phosphate, vitamin D3, magnesium phosphate, zinc salt, selenium salt and vitamin B6, more preferably, based on 100 parts by weight of calcium phosphate, vitamin D3 0.0005 to 0.002 parts by weight, phosphoric acid 35 to 45 parts by weight of magnesium, 0.5 to 2 parts by weight of zinc salt, 0.0001 to 0.0004 parts by weight of selenium salt, and 0.1 to 0.4 parts by weight of vitamin B6, more preferably, 0.0007 to 0.0015 parts by weight of vitamin D3 based on 100 parts by weight of calcium phosphate parts, 37 to 43 parts by weight of magnesium phosphate, 0.7 to 1.5 parts by weight of zinc salt, 0.00015 to 0.0003 parts by weight of selenium salt, and 0.15 to 0.3 parts by weight of vitamin B6.
상기와 같은 효과와 함께, 특히 조골세포의 골분화 촉진 효과를 위해, 본 발명의 칼슘 영양제 조성물은 바람직하게는 인산칼슘 100중량부를 기준으로 피쉬콜라겐 150 내지 250중량부를 더 포함한다. 이때, 상기와 같은 효과를 위해, 피쉬콜라겐의 비율을, 보다 바람직하게는, 인산칼슘 100중량부를 기준으로 170 내지 230중량부, 더욱 바람직하게는, 인산칼슘 100중량부를 기준으로 180 내지 220중량부로 한다.In addition to the above effects, in particular for the effect of promoting osteoblast differentiation of osteoblasts, the calcium nutrient composition of the present invention preferably further comprises 150 to 250 parts by weight of fish collagen based on 100 parts by weight of calcium phosphate. At this time, for the above effect, the ratio of fish collagen is, more preferably, 170 to 230 parts by weight based on 100 parts by weight of calcium phosphate, more preferably 180 to 220 parts by weight based on 100 parts by weight of calcium phosphate. do.
또한, 상기 조골세포의 골분화 촉진 효과를 포함한 본 발명의 효과를 위해, 본 발명의 칼슘 영양제 조성물은 바람직하게는 인산칼슘 100중량부를 기준으로 폴리감마글루탐산 4 내지 10중량부를 더 포함한다. 이때, 상기와 같은 효과를 위해, 폴리감마글루탐산의 비율을, 보다 바람직하게는, 인산칼슘 100중량부를 기준으로 5 내지 9중량부, 더욱 바람직하게는 6 내지 7중량부로 한다.In addition, for the effects of the present invention, including the osteoblast differentiation promoting effect, the calcium nutrient composition of the present invention preferably further comprises 4 to 10 parts by weight of polygamma-glutamic acid based on 100 parts by weight of calcium phosphate. At this time, for the above effect, the ratio of polygamma-glutamic acid is, more preferably, 5 to 9 parts by weight, more preferably 6 to 7 parts by weight, based on 100 parts by weight of calcium phosphate.
본 발명에서 피쉬콜라겐은 바람직하게는 분자량 200 내지 500달톤(Da)의 저분자 피쉬콜라겐이며, 보다 바람직하게는 분자량 200 내지 400달톤의 저분자 피쉬콜라겐이며, 보다 바람직하게는 분자량 250 내지 350달톤의 저분자 피쉬콜라겐이다.In the present invention, the fish collagen is preferably a low molecular weight fish collagen having a molecular weight of 200 to 500 Daltons (Da), more preferably a low molecular weight fish collagen having a molecular weight of 200 to 400 Daltons, and more preferably a low molecular weight fish having a molecular weight of 250 to 350 Daltons. is collagen.
일 실시형태에서, 본 발명의 칼슘 영양제 조성물은 인산칼슘, 비타민 D3, 인산마그네슘, 아연염, 셀레늄염 및 비타민 B6 만으로 이루어지거나, 여기에 피쉬콜라겐 만이, 또는 피쉬콜라겐과 폴리감마글루탐산 만이 포함되어 이루어진다.In one embodiment, the calcium nutrient composition of the present invention consists only of calcium phosphate, vitamin D3, magnesium phosphate, zinc salt, selenium salt and vitamin B6, or only fish collagen, or fish collagen and polygamma glutamic acid. .
다른 실시형태에서, 본 발명의 칼슘 영양제 조성물은 인산칼슘, 비타민 D3, 인산마그네슘, 아연염, 셀레늄염, 비타민 B6, 피쉬콜라겐 및 폴리감마글루탐산 이외의 다른 성분이 포함되어 이루어진다. 이때 다른 성분에는 예를 들어 칼슘 영양제에 통상적으로 사용되는 부형제 등의 첨가물질이 포함될 수 있으며, 본 발명의 칼슘 영양제 조성물에 포함되어 본 발명의 목적하는 효과에 악영향을 미치지 않아야 할 것이다.In another embodiment, the calcium nutrient composition of the present invention comprises other components other than calcium phosphate, vitamin D3, magnesium phosphate, zinc salt, selenium salt, vitamin B6, fish collagen and polygamma glutamic acid. At this time, other ingredients may include, for example, additives such as excipients commonly used in calcium supplements, and should not be included in the calcium supplement composition of the present invention to adversely affect the intended effect of the present invention.
본 발명의 칼슘 영양제 조성물은 바람직하게는 1일 용량당 800 내지 1200㎎으로 인산칼슘을 포함하며, 이러한 인산칼슘의 양을 기준으로 상기 제시된 비율에 따라 비타민 D3, 인산마그네슘, 아연염, 셀레늄염 및 비타민 B6을 포함한다. 마찬가지로 피쉬콜라겐을 포함하거나 피쉬콜라겐과 함께 폴리감마글루탐산을 포함하는 경우에도 1일 용량당 800 내지 1200㎎의 인산칼슘 양을 기준으로 상기 제시된 비율에 따라 피쉬콜라겐 및/또는 폴리감마글루탐산을 포함한다.The calcium nutrient composition of the present invention preferably contains calcium phosphate in an amount of 800 to 1200 mg per daily dose, and vitamin D3, magnesium phosphate, zinc salt, selenium salt and Contains vitamin B6. Similarly, even when fish collagen is included or polygamma glutamic acid is included together with fish collagen, fish collagen and / or polygamma glutamic acid are included according to the ratio given above based on the amount of calcium phosphate of 800 to 1200 mg per daily dose.
보다 바람직하게는, 본 발명의 칼슘 영양제 조성물은, 1일 용량당, 인산칼슘 900 내지 1100㎎, 비타민 D3 7 내지 13㎍, 인산마그네슘 370 내지 430㎎, 아연염 7 내지 13㎎, 셀레늄염 1 내지 3㎍ 및 비타민 B6 1 내지 3㎎을 포함한다.More preferably, the calcium nutrient composition of the present invention, per daily dose, calcium phosphate 900 to 1100 mg, vitamin D3 7 to 13 μg, magnesium phosphate 370 to 430 mg, zinc salt 7 to 13 mg,
보다 바람직하게는, 본 발명의 칼슘 영양제 조성물은, 상기 인산칼슘, 비타민 D3, 인산마그네슘, 아연염, 셀레늄염 및 비타민 B6과 함께, 1일 용량당, 피쉬콜라겐 1700 내지 2300㎎을 더 포함한다.More preferably, the calcium nutrient composition of the present invention, together with the calcium phosphate, vitamin D3, magnesium phosphate, zinc salt, selenium salt and vitamin B6, per daily dose, further comprises 1700 to 2300 mg of fish collagen.
보다 바람직하게는, 본 발명의 칼슘 영양제 조성물은, 상기 인산칼슘, 비타민 D3, 인산마그네슘, 아연염, 셀레늄염, 비타민 B6 및 피쉬콜라겐과 함께, 1일 용량당, 폴리감마글루탐산 60 내지 70㎎을 더 포함한다.More preferably, the calcium nutrient composition of the present invention, together with the calcium phosphate, vitamin D3, magnesium phosphate, zinc salt, selenium salt, vitamin B6 and fish collagen, per daily dose, 60 to 70 mg of polygammaglutamic acid include more
본 발명의 칼슘 영양제 조성물은 다양하게 제제화될 수 있다. 예를 들어, 상기 성분들이 혼합된 형태로 제제화되거나, 약학적 및/또는 식품학적으로 허용가능한 통상적인 담체 및/또는 첨가제를 선택하여 통상적인 약학적 또는 식품학적 제제로 제제화될 수 있다.The calcium nutrient composition of the present invention may be formulated in various ways. For example, the above ingredients may be formulated in a mixed form, or may be formulated as a conventional pharmaceutical or food product by selecting a pharmaceutically and/or food-acceptable conventional carrier and/or additive.
이에 본 발명은 상기와 같이 제시된 1일 용량당 각 성분의 양으로 제제화된 칼슘 영양제 또한 제공한다.Accordingly, the present invention also provides a calcium nutritional supplement formulated in the amount of each component per daily dose presented as described above.
바람직하게는, 본 발명의 칼슘 영양제는 젤리의 형태이다. 이러한 젤리 형태는 피쉬콜라겐이 포함된 조성물에 물을 첨가하는 방법으로 제조할 수 있다.Preferably, the calcium nutrient of the present invention is in the form of jelly. This jelly form can be prepared by adding water to a composition containing fish collagen.
바람직하게는, 본 발명의 칼슘 영양제는 1일 2회에 1회당 1개의 제제(예를 들어, 1개의 젤리 형태의 제제)를 복용하도록 제공되는 제제로서, 1개의 제제에 인산칼슘 450 내지 550㎎, 비타민 D3 3.5 내지 6.5㎍, 인산마그네슘 185 내지 215㎎, 아연염 3.5 내지 6.5㎎, 셀레늄염 0.5 내지 1.5㎍ 및 비타민 B6 0.5 내지 1.5㎎을 포함한다. 보다 바람직하게는, 상기 인산칼슘, 비타민 D3, 인산마그네슘, 아연염, 셀레늄염 및 비타민 B6과 함께, 피쉬콜라겐 850 내지 1150㎎을 더 포함한다. 보다 바람직하게는, 상기 인산칼슘, 비타민 D3, 인산마그네슘, 아연염, 셀레늄염, 비타민 B6 및 피쉬콜라겐과 함께, 폴리감마글루탐산 30 내지 35㎎을 더 포함한다.Preferably, the calcium nutrient of the present invention is a formulation provided to take 1 formulation (eg, 1 jelly-form formulation) at a time twice a day, and 450 to 550 mg of calcium phosphate per formulation , vitamin D3 3.5 to 6.5 μg, magnesium phosphate 185 to 215 mg, zinc salt 3.5 to 6.5 mg, selenium salt 0.5 to 1.5 μg, and vitamin B6 0.5 to 1.5 mg. More preferably, together with the calcium phosphate, vitamin D3, magnesium phosphate, zinc salt, selenium salt and vitamin B6, it further comprises 850 to 1150 mg of fish collagen. More preferably, together with the calcium phosphate, vitamin D3, magnesium phosphate, zinc salt, selenium salt, vitamin B6 and fish collagen, it further comprises 30 to 35 mg of polygamma-glutamic acid.
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하기로 한다. 이들 실시예는 단지 본 발명을 예시하기 위한 것이므로, 본 발명의 범위가 이들 실시예에 의해 제한되는 것으로 해석되지는 않는다.Hereinafter, the present invention will be described in more detail through examples. These examples are only for illustrating the present invention, and therefore, the scope of the present invention is not to be construed as being limited by these examples.
[실시예][Example]
실시예 1. 조성물 준비Example 1. Composition Preparation
제3인산칼슘[Ca3(PO4)2·2H2O] 500㎎, 비타민 D3(콜레칼시페롤) 5㎍, 제3인산마그네슘[Mg3(PO4)2·2H2O] 200㎎, 가용성 아연염(2가) 5㎎, 가용성 셀레늄염(6가) 1㎍ 및 비타민 B6(피리독신, 피리독살 또는 피리독사민) 1㎎의 배합비로 조성물을 제조하였다.Calcium triphosphate [Ca 3 (PO 4 ) 2 .2H 2 O] 500 mg, vitamin D3 (cholecalciferol) 5 μg, magnesium triphosphate [Mg 3 (PO 4 ) 2 .2H 2 O] 200 mg , soluble zinc salt (divalent) 5mg, soluble selenium salt (hexavalent) 1㎍, and vitamin B6 (pyridoxine, pyridoxal or pyridoxamine) was prepared at a blending ratio of 1mg.
실시예 2. 조성물의 조골세포 분화 조절 효능 조사Example 2. Investigation of the osteoblast differentiation control efficacy of the composition
hBMSC(human bone marrow stromal cell)를 이용하여 조골세포 분화(osteoblast differentiation)를 유도할 때, 실시예 1의 조성물을 처리하여 분화에 미치는 효능에 대하여 조사하였다. 조골세포 분화를 확인하기 위하여 Alizarin Red S 염색법을 이용하여 미네랄 형성 정도를 측정하였다.When inducing osteoblast differentiation using hBMSC (human bone marrow stromal cell), the efficacy of the composition of Example 1 on differentiation was investigated. To confirm osteoblast differentiation, the degree of mineral formation was measured using Alizarin Red S staining method.
실시예 1의 조성물을 각각 1, 10 및 100㎍/㎖의 농도로 처리한 제1실험군, 실시예 1의 조성물과 함께 약 300Da의 저분자 피쉬콜라겐을 처리한 제2실험군, 및 실시예 1의 조성물 및 약 300Da의 저분자 피쉬콜라겐과 함께 폴리감마글루탐산(PGA)을 처리한 제3실험군의 조골세포 분화를 조사한 결과, 제1실험군의 경우 10㎍/㎖의 농도에서 유의성 있게 약 1.3배 미네랄 형성이 더 많이 되었고, 제2실험군의 경우 100㎍/㎖의 농도에서 약 1.5배, 제3실험군의 경우 100㎍/㎖의 농도에서 약 3배 미네랄 형성이 더 많이 된 것으로 나타났다(도 1 내지 3).The first experimental group treated with the composition of Example 1 at concentrations of 1, 10 and 100 μg/ml, respectively, the second experimental group treated with the low molecular weight fish collagen of about 300Da together with the composition of Example 1, and the composition of Example 1 And as a result of examining the osteoblast differentiation of the third experimental group treated with polygammaglutamic acid (PGA) together with about 300Da low molecular weight fish collagen, in the first experimental group, mineral formation was significantly increased by about 1.3 times at a concentration of 10㎍/㎖ In the case of the second experimental group, it was found that the mineral formation was about 1.5 times greater at the concentration of 100 μg/ml, and about 3 times more at the concentration of 100 μg/ml in the third experimental group ( FIGS. 1 to 3 ).
실시예 3. 제제화Example 3. Formulation
1일 2회 복용(1회당 1개의 포장 내용물 복용)하는 형태로 단위 포장당 아래 표 1과 같은 배합비로 혼합하여 제제화하였다.In the form of taking twice a day (taking one package content per one time), it was formulated by mixing it at the compounding ratio shown in Table 1 below per unit package.
1일 2회 복용(1회당 1개의 젤리 복용)하는 형태로 1개의 젤리 당 아래 표 2 및 3 중 하나의 표와 같은 배합비로 혼합하고 물을 가하여 젤리화하는 방법으로 제제화하였다.In the form of taking twice a day (taking one jelly per one time), it was formulated by mixing one jelly at the same mixing ratio as in one of Tables 2 and 3 below, and adding water to form a jelly.
Claims (4)
인산칼슘 100중량부를 기준으로 비타민 D3 0.0007 내지 0.0015중량부, 인산마그네슘 37 내지 43중량부, 아연염 0.7 내지 1.5중량부, 셀레늄염 0.00015 내지 0.0003중량부, 비타민 B6 0.15 내지 0.3중량부, 피쉬콜라겐 180 내지 220중량부, 및 폴리감마글루탐산 6 내지 7중량부를 포함하며,
상기 피쉬콜라겐은 분자량 250 내지 350달톤(Da)의 저분자 피쉬콜라겐이고,
1일 용량당 800 내지 1200mg으로 인산칼슘을 포함하는 칼슘 영양제 조성물.Contains calcium phosphate, vitamin D3, magnesium phosphate, zinc salt, selenium salt, vitamin B6, fish collagen and polygamma glutamic acid,
Based on 100 parts by weight of calcium phosphate, vitamin D3 0.0007 to 0.0015 parts by weight, magnesium phosphate 37 to 43 parts by weight, zinc salt 0.7 to 1.5 parts by weight, selenium salt 0.00015 to 0.0003 parts by weight, vitamin B6 0.15 to 0.3 parts by weight, fish collagen 180 to 220 parts by weight, and 6 to 7 parts by weight of polygamma-glutamic acid,
The fish collagen is a low molecular weight fish collagen having a molecular weight of 250 to 350 Daltons (Da),
A calcium nutrient composition comprising calcium phosphate in an amount of 800 to 1200 mg per daily dose.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020210164614A KR102417522B1 (en) | 2021-11-25 | 2021-11-25 | Composition for osteogenesis containing calcium, collagen and PGA |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020210164614A KR102417522B1 (en) | 2021-11-25 | 2021-11-25 | Composition for osteogenesis containing calcium, collagen and PGA |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR102417522B1 true KR102417522B1 (en) | 2022-07-07 |
Family
ID=82398352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020210164614A KR102417522B1 (en) | 2021-11-25 | 2021-11-25 | Composition for osteogenesis containing calcium, collagen and PGA |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102417522B1 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101401884B1 (en) | 2012-08-21 | 2014-05-29 | 가톨릭대학교 산학협력단 | Composition for calcium uptake comprising mineral water |
| JP2016520544A (en) * | 2013-04-05 | 2016-07-14 | ネステク ソシエテ アノニム | Composition for use in stimulating bone growth |
| JP2016204323A (en) * | 2015-04-27 | 2016-12-08 | フジ日本精糖株式会社 | Osteogenesis promoter |
-
2021
- 2021-11-25 KR KR1020210164614A patent/KR102417522B1/en active IP Right Grant
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101401884B1 (en) | 2012-08-21 | 2014-05-29 | 가톨릭대학교 산학협력단 | Composition for calcium uptake comprising mineral water |
| JP2016520544A (en) * | 2013-04-05 | 2016-07-14 | ネステク ソシエテ アノニム | Composition for use in stimulating bone growth |
| JP2016204323A (en) * | 2015-04-27 | 2016-12-08 | フジ日本精糖株式会社 | Osteogenesis promoter |
Non-Patent Citations (2)
| Title |
|---|
| iherb.com에 게재된 ‘칼슘 보충제를 최대한 활용하는 5가지 방법’(2020.09.18.)* * |
| 이민숙 외 2명. 한국식품영양과학회지 35(3): 255~261(2006.03.30.)* * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69124223T2 (en) | FOOD ADDITIVES CONTAINING VITAMINS AND MINERALS | |
| Ohta et al. | Dietary fructooligosaccharides prevent osteopenia after gastrectomy in rats | |
| JP4592127B2 (en) | Bone resorption inhibitor | |
| US6265438B1 (en) | Vitamin compatible micronutrient supplement | |
| EP1917959B1 (en) | New medical use of alfa-ketoglutarate | |
| SK122593A3 (en) | Additives containing calcium and vitamin d | |
| CN101166429A (en) | Alimentation composition | |
| CZ24999A3 (en) | Pharmaceutical preparation | |
| CA2819541A1 (en) | Biologically active food supplement for prevention of osteoporosis | |
| DE102007004781A1 (en) | Use of guanidinoacetic acid (salts) for the preparation of a health-promoting agent | |
| CN105494647B (en) | A kind of calcium fortification milk powder and preparation method thereof | |
| KR101577083B1 (en) | Formulas comprising calcium, magnesium, zinc, and vitamine D3 for the prevention and amelioration of osteoporosis | |
| JPH07252156A (en) | Medicine for prevention and therapy of osteoporosis | |
| WO2012099304A1 (en) | Method for preparing high concentration calcium phosphate aqueous solution stable in neutral range | |
| KR102417522B1 (en) | Composition for osteogenesis containing calcium, collagen and PGA | |
| Marija Varnai et al. | Succimer treatment and calcium supplementation reduce tissue lead in suckling rats | |
| ES2370122T3 (en) | FOOD TO STIMULATE THE DIFFERENTIATION OF OSTEOBLASTOS AND INHIBIT THE DIFFERENTIATION OF OSTEOCLASTOS. | |
| JP3459932B2 (en) | Anti-osteoporosis composition | |
| DE19836450A1 (en) | Stable animal feed formulation containing pyruvic acid, e.g. supplement for horse, dog and cat, also contains aminoacid, other organic acid and/or physiologically valuable additive | |
| Rosalen et al. | Effect of copper co-crystallized with sugar on caries development in desalivated rats | |
| Panigrahi et al. | Effects on dietary phosphorus of treating cottonseed meal with crystalline ferrous sulphate for the prevention of brown yolk discolouration | |
| CN108719998A (en) | A kind of oral diet supplement medicament for treating osteoarthritis | |
| JP2004010533A (en) | Chondrogenesis promoter and prophylactic/therapeutic agent for disease derived from cartilage injury | |
| KR100597564B1 (en) | Pharmacuetical compositions comprising Eleutheroside E having bone growth-promoting effects | |
| KIKUNAGA et al. | The bioavailability of magnesium in spinach and the effect of oxalic acid on magnesium utilization examined in diets of magnesium-deficient rats |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |